PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 12857937-7 2003 Cyclosporin A, an inhibitor of the mitochondrial permeability pore, partially decreased mitochondrial depolarization, caspase 3 activation, and caspase 9 activation, suggesting a role for mitochondrial dysfunction in these events. Cyclosporine 0-13 caspase 3 Mus musculus 118-127 16428077-5 2006 Cyclosporin treatment increased caspase 3 activity, hematocrit and osmolality, while urinary protein, creatinine and uric acid were unaltered. Cyclosporine 0-11 caspase 3 Mus musculus 32-41 15033175-5 2004 In YAC46 MSNs, NMDA stimulated significantly higher activation of caspase-3 and caspase-9 but not caspase-8, and NMDA-induced caspase-3 and -9 activation was markedly attenuated by cyclosporin A. Cyclosporine 181-194 caspase 3 Mus musculus 66-75 15033175-5 2004 In YAC46 MSNs, NMDA stimulated significantly higher activation of caspase-3 and caspase-9 but not caspase-8, and NMDA-induced caspase-3 and -9 activation was markedly attenuated by cyclosporin A. Cyclosporine 181-194 caspase 3 Mus musculus 126-142 15641687-6 2004 Administration of cyclosporine A, an inhibitor of mitochondria permeability transition pore only partly inhibited caspase3 activity and reduced DNA damage. Cyclosporine 18-32 caspase 3 Mus musculus 114-122 24163074-8 2014 Caspase-3 activity and terminal deoxynucleotidyl transferase dUTP-mediated nick-end labeling in distal nonnecrotic LV both increased after MI but were lower in CsA-treated mice compared with vehicle (P < 0.05). Cyclosporine 160-163 caspase 3 Mus musculus 0-9 22790389-11 2012 Expression of active caspase-3 was increased in a CsA dose-dependent manner and was colocalized with LC3-II in the injured area of CsA-treated kidneys. Cyclosporine 50-53 caspase 3 Mus musculus 21-30 22790389-11 2012 Expression of active caspase-3 was increased in a CsA dose-dependent manner and was colocalized with LC3-II in the injured area of CsA-treated kidneys. Cyclosporine 131-134 caspase 3 Mus musculus 21-30 16006549-8 2005 CsA treatment significantly reduced caspase 3 activity in control and lpr hearts. Cyclosporine 0-3 caspase 3 Mus musculus 36-45 15604871-16 2005 Dry eye + CsA mice showed less activated caspase-3 staining than the dry eye control and the dry eye + vehicle groups. Cyclosporine 10-13 caspase 3 Mus musculus 41-50 15207740-8 2004 Treatment with CsA or FK506 produced nuclear fragmentation and disruption of the multinucleated osteoclasts and an increase in caspase-3 activity. Cyclosporine 15-18 caspase 3 Mus musculus 127-136 34381450-7 2021 p70 S6 kinase and mTOR were reduced by CsA with/without CHBP at 2 weeks, so were S6 ribosomal protein and GSK-3beta at 8 weeks, with reduced CASP-3 at both time points. Cyclosporine 39-42 caspase 3 Mus musculus 141-147 12123203-7 2002 The CsA group showed significant increases in ICE mRNA (0.21 vs. 0.03 amol/microgram total RNA at 4 weeks, p < 0.05) and CPP32 mRNA (0.18 vs. 0.03 amol/microgram total RNA at 4 weeks, p < 0.05), compared with the VH group. Cyclosporine 4-7 caspase 3 Mus musculus 124-129 12123203-8 2002 The enzymatic activity of ICE (16.6 vs. 7.9 rho mol/microgram/h, p < 0.05) and CPP32 protease (15.6 vs. 2.7 rho mol/microgram/h, p < 0.05) proteases were increased in the CsA group, compared with the VH group. Cyclosporine 177-180 caspase 3 Mus musculus 82-87 10361889-4 1999 Anti-Fas antibody administration elevated CPP32-like protease activity at 3 hr in mouse liver, and this elevation of CPP32-like activity was inhibited by treatment with CsA. Cyclosporine 169-172 caspase 3 Mus musculus 42-47 10361889-4 1999 Anti-Fas antibody administration elevated CPP32-like protease activity at 3 hr in mouse liver, and this elevation of CPP32-like activity was inhibited by treatment with CsA. Cyclosporine 169-172 caspase 3 Mus musculus 117-122 10361889-5 1999 The present results show that CsA treatment inhibits the anti-Fas antibody-induced apoptotic process of hepatitis, at least in part, by affecting a reaction upstream of CPP32-like protease activation. Cyclosporine 30-33 caspase 3 Mus musculus 169-174 34565275-6 2021 CsA increased caspase-3 activity, Bax, TOS, MDA, TAS, and MPO levels, and the administration of DAPA with CsA significantly reduced this increase in levels (p < 0.001, p < 0.001, p < 0.001, p < 0.001, p < 0.001, and p < 0.001, respectively). Cyclosporine 0-3 caspase 3 Mus musculus 14-23 34381450-9 2021 Furthermore, in TCMK-1 cells CsA induced apoptosis was decreased by CHBP and/or CASP-3siRNA treatment. Cyclosporine 29-32 caspase 3 Mus musculus 80-86 34381450-12 2021 CsA divergently affects apoptosis in kidneys and cultured kidney epithelial cells, in which CHBP and/or CASP-3siRNA reduces inflammation and apoptosis. Cyclosporine 0-3 caspase 3 Mus musculus 104-110